Back to discover
Drug

Furosemide

Approved · FDA / EMA
Emerging researchLate-stage development
Also known as Disal, Frusemide, Furoscix, Lasix+6 more

Disal, Frusemide, Furoscix, Lasix, Lo-Aqua, Salix - substance, Furosemid, Furosemida, Furosemidu, Furosemidum.

RxNorm4603ChEMBLCHEMBL35UNII7LXU5N7ZO5
1
Research papers
31
Active clinical trials
6
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Comparison Between the Diuretic Effect of Aminophylline and Furosemide in Adult Patients Undergoing Cardiac Surgical Procedures: A Randomized Controlled Trial

Clinical trial2026-07-26Primary completion · ClinicalTrials.gov

Indication expansion: FUROSEMIDE INJECTION 80 MG/ 10 ML (NDA209988)

Regulatory2026-07-23FDA

"Comparison of Furosemide Versus Albumin Plus Furosemide in Increasing Urine Output in Critically Ill Patients: A Double-Blind Randomized Clinical Trial"

Clinical trial2026-06-16Results expected Q3 2026 · ClinicalTrials.gov

Bumetanide vs. Furosemide for Adults Hospitalized With Cirrhosis: the BUFF Trial

Clinical trial2026-06-16Results expected Q1 2029 · ClinicalTrials.gov

Furosemide Oral Versus Placebo for Reduction of Hospital Length of Stay in Postpartum Women With Severe Preeclampsia: A Double-Blind, Randomized Controlled Trial

Clinical trial2026-06-15Results expected Q4 2026 · ClinicalTrials.gov

A Two-Part Clinical Study to Evaluate the Effect of Multiple Doses of MK-2828 on Rosuvastatin (Part 1) and Furosemide (Part 2) in Healthy Participants

Clinical trial2026-06-13Completed · ClinicalTrials.gov

Urinary Sodium-Guided Optimization of Diuretic Therapy in Patients With Worsening Heart Failure: Rationale and Design of a Pragmatic Randomized Controlled Trial (SURE-HF Trial)

Clinical trial2026-06-08Results expected Q4 2027 · ClinicalTrials.gov

Goal Directed Fluid Removal With Furosemide in Intensive Care Patients With Fluid Overload - A Randomised, Blinded, Placebo-controlled Trial (GODIF).

Clinical trial2026-06-03Results expected Q2 2027 · ClinicalTrials.gov

Approval: Bopediat (EMA)

Regulatory2026-05-29EMA

Indication expansion: FUROSEMIDE INJECTION 80 MG/ 10 ML (NDA209988)

Regulatory2025-12-22FDA

Indication expansion: FUROSEMIDE INJECTION 80 MG/ 10 ML (NDA209988)

Regulatory2025-03-06FDA

Diuretic strategies in patients with acute decompensated heart failure.

Research2011-03-01The New England journal of medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Furosemide
Aliases & brands
DisalFrusemideFuroscixLasixLo-AquaSalix - substanceFurosemidFurosemidaFurosemiduFurosemidum
RxNorm CUI
4603
ChEMBL ID
CHEMBL35
UNII
7LXU5N7ZO5
Regulatory jurisdictions
emafda

Regulatory timeline

6 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Approval / market entry confirmed across FDA and EMA (2025-03-06 → 2026-07-23)
Earliest approval
2022-10-07
Latest approval
2026-07-23
Authorities
FDA · EMA
Total events
6
fdaU.S. Food and Drug Administration· 5 events
2026-07-23Indication expansionMulti-authority
Indication expansion: FUROSEMIDE INJECTION 80 MG/ 10 ML (NDA209988)
Evidence ↗
2025-12-22Indication expansionMulti-authority
Indication expansion: FUROSEMIDE INJECTION 80 MG/ 10 ML (NDA209988)
Evidence ↗
2025-03-06Indication expansionMulti-authority
Indication expansion: FUROSEMIDE INJECTION 80 MG/ 10 ML (NDA209988)
Evidence ↗
emaEuropean Medicines Agency· 1 event
2026-05-29ApprovalMulti-authority
Approval: Bopediat (EMA)
Indication: Bopediat is indicated in children from birth to less than 18 years of age for the treatment of oedema of cardiac or renal origin, oedema of hepatic origin, and hypertension in… Show full indication

Bopediat is indicated in children from birth to less than 18 years of age for the treatment of oedema of cardiac or renal origin, oedema of hepatic origin, and hypertension in patients with chronic kidney disease.

Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

175 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
175
registered trials across all phases
LATEST COMPLETION 2026
31
Active studies
26
Recruiting
115
Late-stage (III+)
92
Completed
52
Discontinued
PHASE DISTRIBUTIONn = 175
Early Phase 17Phase 127Phase 1 / 27Phase 219Phase 2 / 35Phase 330Phase 442Phase N / A38

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Protocol Based-Furosemide Stress Test to Evaluate Renal Recovery During Continuous Renal Replacement Therapy (FST-STOP): A Randomized Controlled Trial

RecruitingPH IVChiang Mai Universityn=802028

Forebrain Electroneutral Transporters in Salt-sensitive Hypertension: an MRI Study

RecruitingPH IVUniversity of Delawaren=1202028

Optimizing Preeclampsia Postpartum With Point-of-Care Ultrasound: A Pilot Prospective Cohort Study

Not yet recruitingPH IVUniversity of California, Irvinen=962028

Goal Directed Fluid Removal With Furosemide in Intensive Care Patients With Fluid Overload - A Randomised, Blinded, Placebo-controlled Trial (GODIF).

RecruitingPH IVKey trialMorten H. Bestlen=1,0002028

Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure

RecruitingPH IVLakeland Regional Health Systems, Inc.n=6002027

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Two-Part Clinical Study to Evaluate the Effect of Multiple Doses of MK-2828 on Rosuvastatin (Part 1) and Furosemide (Part 2) in Healthy Participants

CompletedPH IMerck Sharp & Dohme LLCn=412026

Impact of Forced Diuresis on the Residual Fragment Rate After Flexible Ureteroscopy for Management of Medium Sized Renal Stones

CompletedN/AKey trialAin Shams Universityn=2,0002025

Transporter Profiling Study for P-glycoprotein 1 (P-gp), Organic Anion Transporter 1 (OAT1), Organic Anion Transporter 3 (OAT3), Organic Cation Transporter 2 (OCT2), Multidrug and Toxin Extrusion Protein 1 (MATE1), Multidrug and Toxin Extrusion Protein 2-K (MATE2-K), Organic Anion Transporting Polypeptide 1B1 (OATP1B1), Organic Anion Transporting Polypeptide 1B3 (OATP1B3) and Breast Cancer Resistance Protein (BCRP) in Healthy Subjects and in Patients With Stage 4 (F4) Liver Fibrosis / Cirrhosis.

CompletedN/ABoehringer Ingelheimn=282024

The Effect of Zongertinib on the Pharmacokinetics of Dabigatran (Part 1) and Rosuvastatin, Metformin and Furosemide Administered as a Cocktail (Part 2) in Healthy Male Subjects (a 2-part, Open-label, 2-period, Fixed-sequence Cross-over Trial)

CompletedPH IBoehringer Ingelheimn=322024

Ultra High Dose Diuretic Strategy for Management of Acute Decompensated Heart Failure - A Randomized, Double-Blind Pilot Trial

CompletedPH IIMayo Clinicn=202024

Furosemide and Creatinine Tubular Stress Test in Order to Measure Proximal Tubule Residual Function: is It Better Than GFR?

CompletedPH IInstituto Nacional de Cardiologia Ignacio Chavezn=502024

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Diuretic strategies in patients with acute decompensated heart failure.

The New England journal of medicine · 2011 · 1,106 cites
Recent papers

Diuretic strategies in patients with acute decompensated heart failure.

The New England journal of medicine · 2011 · 1,106 cites
Journals, researchers & institutions
Top journals
  • The New England journal of medicine1
Leading researchers
  • Anstrom KJ1
  • Bart BA1
  • Braunwald E1
  • Bull DA1
  • Chen HH1
  • Deswal A1
  • Felker GM1
  • Givertz MM1
Leading institutions
free-text, unnormalised
  • Duke University School of Medicine and Duke Heart Center1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.